

On page 26 at line 8:

C5

D. Synthesis of the pentadecapeptide (Ref No. 9405): (SEQ ID NO: 8)

On Page 26 at line 10:

C6

Ch<sub>3</sub>CO-Leu<sup>1</sup>-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe<sup>15</sup> (cyclic disulfide) (SEQ ID NO: 8)

C7

On Page 26 at line 21:  
E. Synthesis of the dicyclo-pentadecapeptide (Ref No. 9408): (SEQ ID NO: 11)

On page 30 at line 6:

C8

Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (cyclic disulfide)  
(SEQ ID NO: 19)

In the Claims

Please amend the claims as follows:

*Sub D*  
1. (Amended) A peptide which comprises an analogue of the carboxyl-terminal sequence of a growth hormone, said carboxyl-terminal sequence containing amino acid residues 177-191 of human growth hormone:

Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (SEQ ID NO: 1),

or a corresponding sequence of a non-human mammalian growth hormone;  
wherein in said analogue

(i) amino acids at positions 182 and 189 of hGH are joined by a bond to promote a cyclic conformation; and/or

(ii) amino acids at positions 183 and 186 of hGH are joined by a salt bridge or a covalent bond;

C9  
over

or an organic or inorganic acid addition salt thereof.

13. (Amended) A peptide of the sequence:

X<sup>1</sup>m-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-X<sup>2</sup>n (SEQ ID NO: 2)

wherein X<sup>1</sup> and X<sup>2</sup> are each selected from the group consisting of L- or D- Arg, His, Lys and Tyr, and m and n are each 0, 1, 2 or 3 with the proviso that at least m or n is 1;

a cyclic disulfide thereof or an organic or inorganic acid addition salt thereof.

14. (Amended) A peptide of the sequence:

Y<sup>1</sup>-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (SEQ ID NO: 3)

wherein Y<sup>1</sup> is selected from the group consisting of the desamino form (H), acetyl (CH<sub>3</sub>CO-) and other acyl groups;

a cyclic disulfide thereof or an organic or inorganic acid addition salt thereof.

15. (Amended) A peptide of the sequence:

Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe-Y<sup>2</sup> (SEQ ID NO: 4),

wherein Y<sup>2</sup> is selected from the group of CONH<sub>2</sub> and alkyl amide groups;

a scyclic disulfide thereof or an organic or inorganic acid addition salt thereof.

16. (Amended) A peptide which is selected from the group consisting of

Leu Arg Ile Val Gln Pen Arg Ser Val Glu Gly Ser Pen Gly Phe (SEQ ID NO: 15),

CH<sub>3</sub>CO- Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 8),

H - Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 12),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe - CONH<sub>2</sub> (SEQ ID NO: 7),

Leu Arg Ile Val Gln Cys Lys Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 10),

Leu Arg Ile Val Gln Cys Lys Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 11),

| (amide bond)

Tyr Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 19),

Lys Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 20),

Lys Lys Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 33),

Ala Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 22),

Leu Lys Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 21),

Leu Arg Ala Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 23),

Leu Arg Lys Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 6),

Leu Arg Ile Ala Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 24),

Leu Arg Ile Val Ala Cys Arg Ser Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 25),

Leu Arg Ile Val Gln Cys Arg Ala Val Glu Gly Ser Cys Gly Phe (SEQ ID NO: 27),

Leu Arg Ile Val Gln Cys Arg Ser Ala Glu Gly Ser Cys Gly Phe (SEQ ID NO: 28),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Ala Ser Cys Gly Phe (SEQ ID NO: 30),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ala Cys Gly Phe (SEQ ID NO: 31),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Ala Phe (SEQ ID NO: 17),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu D-Ala Ser Cys D-Ala Phe (SEQ ID NO: 14),

Leu Arg Ile Val Gln Cys Arg Ser Val Glu Gly Ser Cys Gly Ala (SEQ ID NO: 16),

wherein all amino acids, except for glycine, are of the L-absolute configuration, unless indicated as D-absolute configuration, and the peptide has a cyclic disulfide bond between Cys(182) and Cys(189) or Pen(182) and Pen(189) as appropriate, or an organic or inorganic acid addition salt thereof.

CII 17. (Amended) A method for the treatment of obesity in an animal, which comprises administering to the animal an effective amount of a peptide according to claim 1.

C12 34. (Amended) A method according to claim 17, wherein the peptide is administered orally.

C13 36. (Amended) A pharmaceutical composition for use in the treatment of obesity in an animal, which comprises an effective amount of a peptide according to claim 1, together with one or more pharmaceutically acceptable carriers and/or diluents.